Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionFiera Capital Corp
Latest Disclosed Ownership651,255 shares
Latest Disclosed Value $ 85,796,334
Fiera Capital Corp reports 2.17% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 12, 2026 - Fiera Capital Corp filed a 13F-HR form disclosing ownership of 651,255 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $85,796,334 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 637,408 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 2.17% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 651,255 13,847 2.17 85,796 -5.10 0.1740
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 637,408 157,732 32.88 90,404 34.26 0.2867
2025-11-07 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 479,676 -10,918 -2.23 67,337 9.20 0.2177
2025-08-08 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 490,594 -3,881 -0.78 61,663 12.75 0.2090
2025-05-07 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 494,475 -4,634 -0.93 54,689 -19.73 0.1976
2025-01-29 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 499,109 -17,692 -3.42 68,128 14.41 0.2145
2024-11-01 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 516,801 -11,101 -2.10 59,546 -18.07 0.1791
2024-10-31 2024-06-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 527,902 16,360 3.20 72,676 3.01 0.2253
2024-08-19 2024-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 527,902 16,360 72,676 0.2274
2024-08-01 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 527,902 16,360 72,676 0.1226
2024-08-22 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 511,542 -5,323 -1.03 70,552 3.60 0.2056
2024-05-01 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 511,542 -5,323 70,552 0.2056
2024-08-22 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 516,865 5,497 1.07 68,102 18.38 0.2091
2024-02-08 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 516,865 5,497 68,102 0.2091
2024-08-22 2023-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 511,368 153,393 42.85 57,529 70.42 0.1841
2023-11-09 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 511,368 153,393 57,529 0.1841
2023-08-09 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 357,975 -11,392 -3.08 33,757 -9.71 0.0977
2023-04-26 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 369,367 -3,152 -0.85 37,387 -15.97 0.1117
2023-02-08 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 372,519 -2,568 -0.68 44,494 18.57 0.1383
2022-11-03 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 375,087 -3,719 -0.98 37,526 1.62 0.1346
2022-08-10 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 378,806 363,906 2,442.32 36,926 2,543.24 0.1095
2022-05-09 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,900 -348,972 -95.91 1,397 -95.49 0.0026
2022-05-09 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 383,686 35,971
2022-02-08 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 363,872 -38,600 -9.59 30,991 -19.71 0.0727
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 402,472 -6,390 -1.56 38,601 -2.99 0.0992
2021-08-16 2021-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 408,862 -9,348 -2.24 39,791 -2.16 0.1019
2021-08-11 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 408,862 -9,348 49,881 0.1400
2021-05-11 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 418,210 5,934 1.44 40,671 2.92 0.1171
2021-02-09 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 412,276 126,651 44.34 39,517 43.88 0.1061
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 285,625 285,625 27,465 0.0816
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.